Drug Trial Radar · NCT02258542
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
Last checked: Nov 20, 2026Latest source record: Aug 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,133
Actual
Start
Nov 19, 2014
Primary completion
Oct 18, 2017
Study completion Jul 2, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
Conditions
- Asthma
Interventions
BenralizumabBiological
Benralizumab administered subcutaneously
BenralizumabBiological
Benralizumab administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
- Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
- Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
- Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
- Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
- Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
- Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
- Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI PatientsTime frame: Week 56
- Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)Time frame: Week 108
Locations
429 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Andalusia, Alabama
Research Site
Birmingham, Alabama
Research Site
Scottsboro, Alabama
Research Site
Glendale, Arizona
Research Site
Phoenix, Arizona
Research Site
Alhambra, California
Research Site
Bakersfield, California
Research Site
Newport Beach, California
Research Site
Redondo Beach, California
Research Site
Roseville, California
Research Site
Sacramento, California
Research Site
San Jose, California
Research Site
Stockton, California
Research Site
Walnut Creek, California
Research Site
Westminster, California
Research Site
Woodland, California
Research Site
Colorado Springs, Colorado
Research Site
Denver, Colorado
Research Site
Wheat Ridge, Colorado
Research Site
New Haven, Connecticut
Research Site
Brandon, Florida
Research Site
Clearwater, Florida
Research Site
Cutler Bay, Florida
Research Site
Doral, Florida
Research Site
Hialeah, Florida
Research Site
Hialeah, Florida
Research Site
Homestead, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Orlando, Florida
Research Site
Orlando, Florida
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Albany, Georgia
Research Site
Gainesville, Georgia
Showing 40 of 429 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.